Skip to content

US · INBS · MEDICAL - DIAGNOSTICS & RESEARCH

Intelligent Bio Solutions Inc. (INBS) intrinsic value and stock valuation

$1.39as of 2026-11-21 · Mkt cap 1.28M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Intelligent Bio Solutions Inc. DCF and intrinsic value

InvestorsCraft values INBS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from INBS’s statements →

Intelligent Bio Solutions Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research New York City, NY 10019 ibs.inc

How the business is doing

Fiscal 2017–2025, USD

Revenue
$3.05M+74.2% 5y CAGRd
20172025
Net income
-$-10.57M
20172025
Free cash flow
-$-9.91M
20172025
Total equity
$2.81M
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$3.05M$3.11M$1.26M$0.00$1.98M
Operating income-$-10.64M-$-10.28M-$-12.6M-$-8.34M-$-5.57M
Net income-$-10.57M-$-10.16M-$-10.63M-$-8.31M-$-7.04M
EPSd-$-19.94M-$-31.75M-$-53.15M-$-118.71M-$-140.8M
Operating cash flow-$-9.68M-$-9.57M-$-7.38M-$-3.36M-$-11.3M
Capital expenditure-$-230K-$-220K-$-510K-$-380K-$0.00
Free cash flow-$-9.91M-$-9.79M-$-7.88M-$-3.74M-$-11.3M
Total assets$8.25M$13.8M$10.4M$12.4M$21.9M
Total debt$280K$1.15M$1.92M$0.00$0.00
Net debt-$-740K-$-5.16M$380K-$-8.24M-$-12.57M
Total equity$2.81M$8.18M$3.69M$6.55M$15M
Cash and short-term investments$1.02M$6.3M$1.54M$8.28M$12.6M
Income statement
20252024202320222021
Revenue$3.05M$3.11M$1.26M$0.00$1.98M
Cost of revenue$1.81M$1.69M$930K$0.00$0.00
Gross profit$1.25M$1.43M$330K$0.00$1.98M
Research and development expenses$2.4M$1.67M$510K$3.85M$3.84M
Selling, general and administrative expenses$8.88M$9.26M$8.03M$4.92M$3.36M
Other expenses$610K$780K$4.39M-$-440K$360K
Operating expenses$11.9M$11.7M$12.9M$8.34M$7.55M
Cost and expenses$13.7M$13.4M$13.9M$8.34M$7.55M
Interest income$100K$80K$10K$10K$10K
Interest expense$60K$170K$220K$10K$1.09M
Depreciation and amortization$970K$970K$970K$0.00$5.21M
Ebitda-$-9.45M-$-9.05M-$-9.47M-$-8.33M$0.00
Operating income-$-10.64M-$-10.28M-$-12.6M-$-8.34M-$-5.57M
Total other income/expenses, net$40K$90K$1.93M$0.00-$-1.49M
Income before tax-$-10.6M-$-10.19M-$-10.66M-$-8.33M-$-7.06M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-10.57M-$-10.16M-$-10.63M-$-8.31M-$-7.04M
Weighted average shares outstanding$530K$320K$200K$70K$50K
Weighted average diluted shares outstanding$530K$320K$200K$70K$50K
Balance sheet
20252024202320222021
Cash and short-term investments$1.02M$6.3M$1.54M$8.28M$12.6M
Net receivables$1.6M$980K$830K$1.53M$2.1M
Inventory$640K$780K$980K$0.00$0.00
Total current assets$4.14M$8.53M$3.86M$10.9M$18.2M
Property, plant and equipment, net$320K$870K$1.24M$390K$0.00
Goodwill and intangible assets$3.79M$4.37M$5.26M$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$4.11M$5.24M$6.49M$1.48M$3.65M
Total assets$8.25M$13.8M$10.4M$12.4M$21.9M
Accounts payable$900K$600K$1.2M$720K$1.36M
Short-term debt$280K$1.06M$800K$0.00$0.00
Deferred revenue$2.17M$2.49M$2.34M$0.00$0.00
Total current liabilities$5.35M$5.45M$5.88M$4.66M$3.68M
Long-term debt$0.00$80K$1.12M$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$80K$140K$780K$1.14M$3.17M
Capital lease obligations$80K$360K$580K$0.00$0.00
Total liabilities$5.44M$5.6M$6.67M$5.81M$6.85M
Common stock$70K$30K$20K$10K$140K
Retained earnings-$-62.53M-$-51.96M-$-41.81M-$-31.18M-$-22.87M
Accumulated other comprehensive income (loss)-$-330K-$-710K-$-580K-$-790K-$-660K
Total equity$2.81M$8.18M$3.69M$6.55M$15M
Total investments$0.00$0.00$0.00$50K$0.00
Total debt$280K$1.15M$1.92M$0.00$0.00
Net debt-$-740K-$-5.16M$380K-$-8.24M-$-12.57M
Cash flow statement
20252024202320222021
Net income-$-10.6M-$-10.19M-$-10.66M-$-8.33M-$-7.06M
Depreciation and amortization$1.21M$1.21M$970K$0.00$0.00
Stock-based compensation$240K$230K$260K$0.00$0.00
Change in working capital-$-720K-$-700K$80K$2.44M-$-4.94M
Accounts receivable-$-2.86M-$-10K$590K$2.5M-$-1.03M
Inventory$140K$200K-$-350K$0.00$0.00
Accounts payable$0.00-$-630K$80K$240K-$-970K
Net cash provided by operating activities-$-9.68M-$-9.57M-$-7.38M-$-3.36M-$-11.3M
Investments in property, plant and equipment-$-230K-$-220K-$-510K-$-380K$0.00
Acquisitions, net$0.00$0.00-$-190K$0.00$0.00
Net cash used for investing activities-$-230K-$-220K-$-690K-$-880K$0.00
Common stock issued$4.59M$12.9M$2.55M$0.00$21.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$4.6M$14.6M$1.44M$0.00$23.4M
Net change in cash-$-5.28M$4.77M-$-6.7M-$-4.34M$12.2M
Cash at end of period$1.02M$6.3M$1.54M$8.24M$12.6M
Operating cash flow-$-9.68M-$-9.57M-$-7.38M-$-3.36M-$-11.3M
Capital expenditure-$-230K-$-220K-$-510K-$-380K-$0.00
Free cash flow-$-9.91M-$-9.79M-$-7.88M-$-3.74M-$-11.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Intelligent Bio Solutions Inc.

        Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

        CEO
        Harry Simeonidis
        Employees
        55
        Beta
        4.17

        Explore

        Frequently asked questions

        What is the intrinsic value of Intelligent Bio Solutions Inc. (INBS)?

        Intelligent Bio Solutions Inc. (INBS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is INBS undervalued?

        INBS trades at a price of $1.39 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.